Projected budget impact and access to new drugs in Brazil

Brazil's Constitution defines health as a right of all and a duty of the State, and the Unified Health System (SUS) translates that promise into free access to medicines at the point of care.1 Since Law 12,401/2011, new drugs enter the SUS through the National Committee for Health Technology Incorporation (CONITEC, for the acronym in Portuguese), which must weigh clinical evidence, cost-effectiveness and budget impact.2 In The Lancet Regional Health – Americas, Curado and colleagues3 step back from case-by-case appraisal and ask a system-level question: taken together, did the projected budget impacts of the 199 drugs incorporated between 2012 and 2024 add up to something the SUS could afford?

Authors

Institutions

Publication Details

Journal
The Lancet Regional Health - Americas
Published
2026-11-17
DOI
https://doi.org/10.1016/j.lana.2026.101712
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Projected budget impact and access to new drugs in Brazil

Ângelo Maiolino
4 links
The Lancet Regional Health - Americas
Pharmaceutical Economics and Policy
article

Projected budget impact and access to new drugs in Brazil

Ângelo Maiolino
article en

Abstract

Brazil's Constitution defines health as a right of all and a duty of the State, and the Unified Health System (SUS) translates that promise into free access to medicines at the point of care.1 Since Law 12,401/2011, new drugs enter the SUS through the National Committee for Health Technology Incorporation (CONITEC, for the acronym in Portuguese), which must weigh clinical evidence, cost-effectiveness and budget impact.2 In The Lancet Regional Health – Americas, Curado and colleagues3 step back from case-by-case appraisal and ask a system-level question: taken together, did the projected budget impacts of the 199 drugs incorporated between 2012 and 2024 add up to something the SUS could afford?

The Lancet Regional Health - AmericasVol. 64
Universidade Federal do Rio de Janeiro (BR), Instituto de Oncologia do Paraná (BR), Sociedade Brasileira de Oncologia Clínica (BR)
Good health and well-being
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon